KRAS-driven MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway, which might provide a mechanistic rationale for the use of a MEK inhibitor as an adjuvant, in combination with standard of care, to prevent the recurrence of CRLM in KRAS mutant CRC patients after receiving liver resection, however, further investigation is needed. The gene discussed is DNMT1; the disease is colorectal carcinoma.